Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Pheochromocytoma 1Paraganglioma 1Ovarian Neoplasms 1Kidney Neoplasms 1Gastrointestinal Stromal Tumors 1Fallopian Tube Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Imatinib Mesylate 8Specimen Handling 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Ipilimumab 2CTLA-4 Antigen 2temsirolimus 1rubitecan 1romidepsin 1oblimersen 1motexafin lutetium 1guadecitabine 1alvocidib 1Sorafenib 1Sirolimus 1Semaxinib 1Rogaratinib 1Nivolumab 1Leucovorin 1Irinotecan 1Immunoglobulin G 1HhAntag691 1Floxuridine 1Erlotinib Hydrochloride 1Doxorubicin 1Disulfides 1Dasatinib 1Cetuximab 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Gastrointestinal Stromal Tumors × guadecitabine × Clear all
NCT03165721 2026-02-18

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
9 enrolled 11 charts
CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Kidney Neoplasms, Paraganglioma, Pheochromocytoma, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡